SF2806 (Legislative Session 94 (2025-2026))
Prescription monitoring program provisions modifications
Related bill: HF2624
AI Generated Summary
Purpose of the Bill
The bill aims to revise Minnesota's prescription monitoring program to improve the tracking and administration of controlled substances within the state.
Main Provisions
Definitions and Scope: Updates definitions related to controlled substances and specifies the substances included, such as butalbital, gabapentin, and opioid antagonists approved for overdose reversal.
Prescription Monitoring System: Modifies requirements for an electronic reporting system to ensure that controlled substances prescribed and dispensed are tracked accurately.
Reporting Requirements: Demands dispensers to report detailed information about prescriptions, including prescriber and dispenser identifiers, patient information, and prescription details. It also sets standards for data format and reporting timelines.
Data Management: Establishes guidelines on how prescription data should be accessed, maintained, and used by permissible users, such as healthcare providers, pharmacists, and government bodies, for monitoring and regulatory purposes.
Access and Use of Data: Outlines who can access the prescription data and under what circumstances. Specific provisions restrict access to prevent misuse and maintain patient privacy, with clear rules about data encryption and use limitations.
Patient Rights and Information: Provides patients with the right to request and access their prescription data history, including who has accessed their data.
Data Retention and Security: Prescribes time limits on how long data can be retained and requires all access to be logged and subject to random audits to ensure compliance with privacy rules.
Significant Changes to Existing Law
- Expands the list of controlled reportable substances and includes opioid antagonists.
- Introduces more detailed reporting and verification processes for dispensers.
- Allows patients greater access to their prescription data to monitor who has accessed their records.
- Imposes stricter rules on data retention and requires de-identification of information after certain periods to enhance privacy protections.
- Mandates regular audits for potential misuse and requires comprehensive security measures for electronic data access.
Relevant Terms
- Prescription monitoring program
- Controlled substances
- Electronic reporting system
- Dispenser
- Prescriber
- Opioid antagonists
- Data privacy and security
- Patient access rights
Bill text versions
- Introduction PDF file
Actions
| Date | Chamber | Where | Type | Name | Committee Name |
|---|---|---|---|---|---|
| March 19, 2025 | Senate | Floor | Action | Introduction and first reading | |
| March 19, 2025 | Senate | Floor | Action | Referred to | Health and Human Services |
Citations
[
{
"analysis": {
"added": [
"Includes new substances like butalbital and gabapentin in the definition."
],
"removed": [
""
],
"summary": "The bill amends definitions related to controlled substances in the context of prescription monitoring, specifically referencing substances listed in section 152.02.",
"modified": [
"Clarified which substances fall under controlled reportable substances."
]
},
"citation": "152.02",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "The bill refers to existing statutes regarding veterinarian practice concerning dispensing regulations.",
"modified": [
"Specifies that veterinarians are excluded from being classified as dispensers under this context."
]
},
"citation": "156.18",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Reference to authorized prescribers of controlled substances under the existing statute.",
"modified": [
"Refines who is legally considered a prescriber for these substances."
]
},
"citation": "152.12",
"subdivision": "subdivision 1 or 2"
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Refers to current regulations for automated drug distribution systems in certain care facilities.",
"modified": [
"Clarified procedures for drugs distributed through automated systems."
]
},
"citation": "151.58",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Cited to define private data on individuals relevant to prescription data access.",
"modified": [
"Ensures protection of individual data as per private data statutes."
]
},
"citation": "13.02",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Identifies health-related licensing boards relating to permissible use access.",
"modified": [
"Clarifies which boards can access prescription data under investigation."
]
},
"citation": "214.01",
"subdivision": "subdivision 2"
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Refers to the Health Professionals Services Program as a permissible user under prescription monitoring.",
"modified": [
"Determines the program participants' data access rights within the prescription monitoring program."
]
},
"citation": "214.31",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Provides guidelines about health care directives in context to data access by health care agents.",
"modified": [
"Clarifies health care agents' data access when directed by a health directive."
]
},
"citation": "145C",
"subdivision": ""
},
{
"analysis": {
"added": [
""
],
"removed": [
""
],
"summary": "Points to the opioid prescribing improvement program for certain prescription protocols.",
"modified": [
"Sets out prescription protocols post-surgery under this program."
]
},
"citation": "256B.0638",
"subdivision": ""
}
]